Advocacy Campaigns
CCA works to advocate for the IBD community in a range of ways:
- Lobbying governments for funding
- Providing submissions about health policy
- Raising consumer needs to researchers and industry
- Awareness campaigns
Current advocacy campaigns
Help improve the quality of life for regional Australians living with chronic inflammatory conditions
Crohn’s & Colitis Australia has been working in partnership with eight other organisations to seek the support of government for A Proposal to Fund Nurses in Regional Centres to Support People Living with Chronic Inflammatory Conditions. Learn about how you can help secure support for this proposal for an election commitment from politicians and candidates during the 2022 Federal election.
Review of the National Medicines Policy
Closed October 2021.
Have your say on PBD listings for IBD Medications – March 2022
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on an ulcerative colitis medication.
If you have experience taking IBD medications you may like to provide feedback on what difference it has made to your life by email to [email protected].
CCA will then forward your comments grouped with those of others to PBAC.
The closing date for comments to CCA is May 25th 2022.
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | OZANIMOD Capsule 920 micrograms Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms Zeposia® Celgene Pty Limited | Ulcerative Colitis | To request a General Schedule Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Adalimumab All PBS-listed forms Yuflyma® Celltrion Healthcare Australia Pty Ltd | Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn’s disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa | To request listing of adalimumab biosimilar under the same conditions as its reference biologic. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Risanknizuman Solution concentrate for I.V. infusion 600 mg in 10 mL Injection 360 mg in 2.4 mL in pre-filled cartridge Skyrizi® AbbVie Pty Ltd | Crohn’s disease | To request General Schedule Authority Required (Written) listings for the treatment of severe Crohn’s disease and for complex refractory fistulising Crohn’s disease. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Upadacitinib Tablet 15 mg Tablet 30 mg Tablet 45 mg Rinvoq® AbbVie Pty Ltd | Ulcerative colitis | To request a General Schedule Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis, in patients who are contraindicated to, or whose disease has not adequately responded to conventional therapies. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Ustekinumab Injection 90 mg in 1 mL pre-filled syringe Stelara® Janssen-Cilag Pty Ltd | Severe Crohn disease Severe chronic plaque psoriasis | To request a General Schedule Authority Required (Written) listing of a new form for the treatment of patients with Crohn’s disease and chronic plaque psoriasis. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Ustekinumab Injection 90 mg in 1 mL pre-filled syringe Solution concentrate for I.V. infusion 130 mg in 26 mL Stelara® Janssen-Cilag Pty Ltd | Ulcerative colitis | To request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listings for the treatment of moderate to severe ulcerative colitis, in patients who are contraindicated to, or whose disease has not adequately responded to conventional therapies. |
| Submission type | Drug Name, form(s), strength(s) and Sponsor | Drug Type and Use | Listing requested by Sponsor / Purpose of Submission |
|---|---|---|---|
| Change to PBS listing | Teduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes] Revestive® Takeda Pharmaceuticals Australia Pty. Ltd (Sub-committee report DUSC Analysis) | Type III Short Bowel Syndrome with intestinal failure | To compare the predicted and actual utilisation of teduglutide for Type III Short Bowel Syndrome with intestinal failure in the first 24 months of PBS listing. |